Copy to clipboard 
BONESUPPORT reported 4Q23 orthopedic sales of SEKm 172.7 ($16.8 million USD), +67.4% compared to the fourth quarter of 2022. The company generated SEKm 591.1 ($57.3 million USD) during 2023 and grew 79.8% compared to the prior year.
The FDA market authorization for CERAMENT G in 2022 drove significant growth for the company in 2023. North American sales grew +104% for the year, with drug-eluting versions of CERAMENT (G and V) accounting for more than half of those sales. CERAMENT G started to cannibalize CERAMENT BVF (Bone Void Filler) sales, but new customer conversions offset those losses.
Fourth quarter sales in Europe and the rest of the world increased 38%, driven by increased market share. BONESUPPORT also joined a small group of companies with a fully MDR-certified product portfolio as CERAMENT BVF and CERAMENT V received CE marking under MDR. The company’s Quality Management System and CERAMENT G received the same certifications earlier in the year.
BONESUPPORT expects 2024 sales of approximately $80 million, reflecting 40% growth. Additionally, the company plans to expand into spinal fusion and submit an FDA application for CERAMENT V in the first quarter of 2025.
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 4Q23 | 4Q22 | $ Chg | % Chg |
|---|---|---|---|---|
| Orthobiologics | $16.8 | $10.0 | $6.7 | 67.4% |
| Segment | FY23 | FY22 | $ Chg | % Chg |
|---|---|---|---|---|
| Orthobiologics | $57.3 | $31.9 | $25.4 | 79.8% |
Orthopedic Sales by Geography
| Region | 4Q23 | 4Q22 | $ Chg | % Chg |
|---|---|---|---|---|
| North America | $12.8 | $7.1 | $5.6 | 79.4% |
| EU and ROW | $4.0 | $2.9 | $1.1 | 37.8% |
| Total | $16.8 | $10.0 | $6.7 | 67.4% |
| Region | FY23 | FY22 | $ Chg | % Chg |
|---|---|---|---|---|
| North America | $42.9 | $21.0 | $21.9 | 104% |
| EU and ROW | $14.4 | $10.9 | $3.6 | 32.8% |
| Total | $57.3 | $31.9 | $25.4 | 79.8% |
BONESUPPORT reported 4Q23 orthopedic sales of SEKm 172.7 ($16.8 million USD), +67.4% compared to the fourth quarter of 2022. The company generated SEKm 591.1 ($57.3 million USD) during 2023 and grew 79.8% compared to the prior year.
The FDA market authorization for CERAMENT G in 2022 drove significant growth for the company in 2023....
BONESUPPORT reported 4Q23 orthopedic sales of SEKm 172.7 ($16.8 million USD), +67.4% compared to the fourth quarter of 2022. The company generated SEKm 591.1 ($57.3 million USD) during 2023 and grew 79.8% compared to the prior year.
The FDA market authorization for CERAMENT G in 2022 drove significant growth for the company in 2023. North American sales grew +104% for the year, with drug-eluting versions of CERAMENT (G and V) accounting for more than half of those sales. CERAMENT G started to cannibalize CERAMENT BVF (Bone Void Filler) sales, but new customer conversions offset those losses.
Fourth quarter sales in Europe and the rest of the world increased 38%, driven by increased market share. BONESUPPORT also joined a small group of companies with a fully MDR-certified product portfolio as CERAMENT BVF and CERAMENT V received CE marking under MDR. The company’s Quality Management System and CERAMENT G received the same certifications earlier in the year.
BONESUPPORT expects 2024 sales of approximately $80 million, reflecting 40% growth. Additionally, the company plans to expand into spinal fusion and submit an FDA application for CERAMENT V in the first quarter of 2025.
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 4Q23 | 4Q22 | $ Chg | % Chg |
|---|---|---|---|---|
| Orthobiologics | $16.8 | $10.0 | $6.7 | 67.4% |
| Segment | FY23 | FY22 | $ Chg | % Chg |
|---|---|---|---|---|
| Orthobiologics | $57.3 | $31.9 | $25.4 | 79.8% |
Orthopedic Sales by Geography
| Region | 4Q23 | 4Q22 | $ Chg | % Chg |
|---|---|---|---|---|
| North America | $12.8 | $7.1 | $5.6 | 79.4% |
| EU and ROW | $4.0 | $2.9 | $1.1 | 37.8% |
| Total | $16.8 | $10.0 | $6.7 | 67.4% |
| Region | FY23 | FY22 | $ Chg | % Chg |
|---|---|---|---|---|
| North America | $42.9 | $21.0 | $21.9 | 104% |
| EU and ROW | $14.4 | $10.9 | $3.6 | 32.8% |
| Total | $57.3 | $31.9 | $25.4 | 79.8% |
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
